UPDATE: Jefferies Raises PT to $23 on Solazyme Post Q3 Beat
Jefferies reiterated its Buy rating on Solazyme (NASDAQ: SZYM) and raised its price target from $22 to $23.
Jefferies commented, "Q3 was $0.06 better than consensus ($0.05 above our forecast). The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."
Solazyme closed at $7.09 on Wednesday.
Latest Ratings for SZYM
|Mar 2016||Goldman Sachs||Maintains||Neutral|
|Nov 2014||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
|Nov 2014||Credit Suisse||Maintains||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.